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Review
Early screening of type 2 diabetes mellitus (DM), a hyperglycemic status associated condition, is essential for preventive treatment and effective delay of
diabetes clinical complications [1]. However, testing for hyperglycemic status often requires invasive and painful blood testing, limiting its large-scale
usefulness. To overcome this constraint salivary glucose assays have recently being studied with the purpose of screening hyperglycemia and type 2 DM
[2]. Literature results regarding blood and salivary glucose relationship in diabetics or in healthy individuals are controversial. On the other hand, to the
best of our knowledge no validation has been done on type 2 DM / hyperglycaemia detection models based on salivary glucose. We have performed a
systematic review and meta-analysis on those studies and cross-validated a type 2 DM / hyperglycemic status predictor model based on salivary glucose.
Experimental Methods
• On our global meta-analysis of standardized mean differences on
salivary glucose levels results show an overall large positive effect of
type 2 DM over salivary glucose (Hedge's g  > 1).
• The logistic models showed a good accuracy on our sample predicting
both hyperglycemia (81,0%) and type 2 DM (84,5%), while in the
external data cross-validation accuracy was lower (65,5% and 69,0%,
respectively). While our prediction models are well fitted for our
Portuguese sample, cross-validation results using both Brazilian and
Indian data showed a significant decrease on accuracy, suggesting that
hyperglycemia status / type 2 DM prediction from salivary glucose
should only be based on region specific models.
Conclusion
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We conducted a meta-analysis of
peer-reviewed published articles
that reported data regarding mean
salivary glucose levels for type 2
DM and non-diabetic individuals
combined with our own results [3].
Furthermore, we used our blood
and salivary glucose data from
type 2 diabetics and healthy
individuals to build type 2 DM /
hyperglycemia status prediction
models. These logistic models
were cross-validated against
external data (Brazil and India) and
accuracy was evaluated through
ROC curve analysis.
p2 + 2pq + q2 = 1
Figure 2 - Subgroup forest plot of type 2 DM mean salivary glucose levels studies. Studies have been grouped according to the type 2 DM group
allocation: with or without subsets. Hedge's g (standardized mean difference) effect size estimates have been calculated with 95% confidence
intervals and are shown in the figure. Area of squares represents sample size, continuous horizontal lines and diamonds width represents 95%
confidence interval. Yellow diamonds center indicates the subgroup pooled estimates while the blue diamond center and the vertical red dotted line
both point to the overall pooled estimate.
Our results show that salivary glucose has potential to be used as type 2 DM biomarker. If associated with the development of sensitive portable
technology to measure salivary glucose this will allow a less painful and invasive method for type 2 DM screening in large cohorts. Even if at present,
due to several limitations, salivary glucose per se may not show enough cross-validation performance to be used as an global and autonomous DM type
2 biomarker, our results suggest that it provides valuable information, and in the future may be combined with other salivary biomarkers to create an
effective high sensitivity/specificity DM type 2 large-scale screening system.
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Figure 1 - Flow of study selection for mean salivary glucose levels. *Studies were excluded unless contained salivary glucose data (means, standard
deviations and sample size) obtained from strictly diabetes mellitus type 2 patients and non-diabetic controls unstimulated whole saliva collected after
a minimum fast period of 2 hours. Were also excluded if the full-text article were not available and the author(s) failed in sending a copy after contact
request or failed in giving back supplementary required data inexistent in the original article. Records containing data already published in other
article were also excluded.
Results
Figure 3 – A: ROC curve for hyperglycemia status prediction with a logistic model based on salivary glucose trained with the Portuguese sample set
; B: ROC curve for type 2 DM status prediction with a logistic model based on salivary glucose trained with the Portuguese sample set.
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